33747-08-9

Upstream product

• 1193-20-0 2-methyltetrahydro-4H-pyran-4-one 
• 33747-08-9 cis-2-methyltetrahydro-2H-pyran-4-ol 
• 627-27-0 homoalylic alcohol 
• 75-07-0 acetaldehyde 

Downstream Products

• 146502-48-9 (2R,4S)-4-(3-Benzyloxy-5-fluoro-phenyl)-2-methyl-tetrahydro-pyran-4-ol 
• 146565-09-5 (2R,4R)-4-(3-Benzyloxy-5-fluoro-phenyl)-2-methyl-tetrahydro-pyran-4-ol 
• 146608-99-3 (2R,4S)-4-(3-Benzyloxy-5-fluoro-phenyl)-4-methoxy-2-methyl-tetrahydro-pyran 
• 146565-12-0 (2R,4R)-4-(3-Benzyloxy-5-fluoro-phenyl)-4-methoxy-2-methyl-tetrahydro-pyran 
• 1193-20-0 2-methyltetrahydro-4H-pyran-4-one 
• 33747-08-9 (2R,4R)-2-methyltetrahydro-2H-pyran-4-ol 
• 75-07-0 acetaldehyde 
• 82110-13-2 (2S,4S)-4-hydroxy-2-methyl-3,4,5,6-tetrahydro-2H-pyran 

Relevant academic research and scientific papers

CYCLIC SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES

The present invention provides novel cyclic substituted imidazo[4,5- c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof, wherein R1, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors

The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Utilizing on- and off-line monitoring tools to follow a kinetic resolution step during flow synthesis

In situ reaction monitoring tools offer the ability to track the progress of a synthetic reaction in real time to facilitate reaction optimization and provide kinetic/mechanistic insight. Herein, we report the utilization of flow NMR, flow IR, and other off-line spectroscopy tools to monitor the progress of a flow chemistry reaction. The on-line and off-line tools were selected to facilitate the stereoselective kinetic resolution of a key racemic monomer, which lacked a chromophore, making conventional reaction monitoring difficult. Copyright

Enzymes in Organic Synthesis. 25. Heterocyclic Ketones as Substrates of Horse Liver Alcohol Dehydrogenase. Highly Stereoselective Reductions of 2-Substituted Tetrahydropyran-4-ones

Horse liver alcohol dehydrogenase (HLADH) has been found to be an efficient catalyst for the reduction of O-heterocyclic ketones.Preparative-scale HLADH-catalyzed reductions of 2-substituted tetrahydropyran-4-ones are enantioselective, with reduction of e